Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, February 2001, p. 605-607, Vol. 45, No. 2
Medical College of Virginia/Virginia
Commonwealth University, Richmond, Virginia 23298
Received 14 August 2000/Returned for modification 5 October
2000/Accepted 20 November 2000
The effect of germinated and nongerminated conidia of
Aspergillus spp. on the fungistatic (National Committee for
Clinical Laboratory Standards document M38-P) and fungicidal activities (MICs and minimal fungicidal concentrations [MFCs] respectively) of
amphotericin B, itraconazole, posaconazole (SCH56592), ravuconazole (BMS-207147), and voriconazole was evaluated. MFCs were the lowest drug
dilutions that showed fewer than three colonies (99.9% killing). Overall, the MICs (0.12 to 4 µg/ml) and MFCs (0.5 to >8 µg/ml) of
all of the agents tested with both inocula were the same or within 2 dilutions for the 72 isolates. Therefore, MICs and MFCs can be obtained
with convenient and standardized nongerminated conidia.
The role of the laboratory in the
selection and monitoring of antifungal therapy has gained greater
attention with the increased incidence of systemic fungal infections
and the growing number of new antifungal agents. The National Committee
for Clinical Laboratory Standards (NCCLS) has proposed standard
conditions for molds (document M38-P) (7, 8, 19, 21).
Although the pathogenic form of most opportunistic molds is the hyphae, document M38-P (19) describes the more convenient and
standardized preparation of nongerminated conidial inoculum
suspensions. Prior studies have compared MICs obtained by employing
either germinated conidia or hyphal suspensions to those obtained with
nongerminated conidia for dematiaceous fungi (13),
Aspergillus spp., and other opportunistic moniliaceous molds
(2, 5, 13, 16-18, 22, 25). However, findings on the
effect of hyphae on MIC determination (2, 5, 13, 17, 22,
25) have been more contradictory than those on the effect of
germinated conidia (16, 18).
Although Aspergillus fumigatus is responsible for the
majority (85 to 90%) of the different clinical manifestations of
Aspergillus infections (4), other
Aspergillus spp. also have been associated with severe
infection in immunocompromised hosts (4, 21, 24, 25). The
purpose of this study was to evaluate the effect of germinated and
nongerminated conidia on MICs and minimal fungicidal concentrations
(MFCs) of amphotericin B, itraconazole, posaconazole (SCH56292),
ravuconazole (BSM-207147), and voriconazole for six Aspergillus spp. following NCCLS document M38-P for MICs
(19).
Seventy-two isolates of Aspergillus spp., each from a
different patient, were evaluated (Tables
1 and
2). A. flavus ATCC 204304 and Candida parapsilosis ATCC 22019 were
included as controls; the MIC ranges for both controls were
within established values (1, 8, 19). Stock inoculum
suspensions were prepared as described in document M38-P
(19) and adjusted spectrophotometrically to optical
densities that ranged from 0.09 to 0.11 (78 to 82% transmittance)
(6). For the nongerminated conidial inocula, the stock
suspensions were diluted 1:50 in the NCCLS standard RPMI 1640 medium
with morpholinepropanesulfonic acid (MOPS) buffer and without
bicarbonate (RPMI). For the germination of conidia, the stock
suspensions were incubated in RPMI at 35°C in a shaker incubator for
7 to 9 h at 180 rpm for five of the six species evaluated;
germination of A. terreus conidia required 14 to 20 h
of incubation. Conidia were considered fully germinated when the length
of the germ tube was at least twice the length of the swollen conidia.
After germination, the stock suspensions were also diluted 1:50 in
RPMI. The final inoculum sizes for both conidial sources ranged from
1.0 × 104 to 3.6 × 104 CFU/ml.
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.2.605-607.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Germinated and Nongerminated Conidial Suspensions for Testing of
Susceptibilities of Aspergillus spp. to Amphotericin B,
Itraconazole, Posaconazole, Ravuconazole, and Voriconazole
ABSTRACT
Top
Abstract
Text
References
TEXT
Top
Abstract
Text
References
TABLE 1.
MICs for germinated and nongerminated conidia of
Aspergillus spp. obtained by the NCCLS broth
microdilution methoda
TABLE 2.
MFCs for germinated and nongerminated conidia of
Aspergillus spp.
MICs of amphotericin B (Bristol-Myers Squibb Pharmaceutical
Research Institute, Wallingford, Conn.), itraconazole (Janssen Pharmaceutica, Titusville, N.J.), posaconazole (SCH56592;
Schering-Plough Research Institute, Kenilworth, N.J.), ravuconazole
(BMS-207147; Bristol-Myers Squibb), and voriconazole (Pfizer
Pharmaceuticals, New York, N.Y.) were determined by the M38-P broth
microdilution method (19). Drug dilutions were prepared at
100 times the final concentrations, followed by further dilutions
(1:50) in RPMI to yield 2 times the final strength required (8 to
0.0078 µg/ml) for the test. Each microdilution well containing 100 µl of the diluted (two times) drug concentration was inoculated with
100 µl of the diluted (two times) inoculum suspensions (the final volume in each well was 200 µl). Both control strains were tested each time a set of isolates was evaluated. Microdilution trays were
incubated at 35°C and visually examined at 48 h for MIC
determination (19); MICs corresponded to either prominent
(
50%, azoles) or complete (amphotericin B) growth inhibition. The in
vitro fungicidal activities each agent were determined as previously
described (9); the MFC was the lowest concentration that
showed fewer than three colonies. MIC AND MFC ranges and MICs and MFCs
for 90% of the isolates tested (MIC90s and
MFC90s, respectively) were obtained for each species-drug
combination tested; MIC50s and MFC50s were
obtained for A. niger.
Since nongerminated conidium suspensions are easier to prepare, they have been traditionally employed for the antifungal susceptibility testing of molds. Because the measurement of conidial susceptibility could represent inhibition of conidial germination instead of hyphal growth by the antifungal agent, hyphae should be the fungal cells tested to evaluate the antifungal susceptibilities of Aspergillus spp. and other opportunistic molds. An alternative procedure is the use of germinated conidia. This study compared the in vitro fungistatic and fungicidal activities of five agents against nongerminated and germinated conidia of Aspergillus isolates. Conidial germination required 7 to 9 h of incubation for five of the six species; germination of A. terreus conidia required 14 to 20 h. Similar results (8 to 10 h) have been reported for A. fumigatus and A. flavus (16, 18). Overall, the MICs of the established and investigational agents obtained with both conidial suspensions were the same or within a 2-dilution range (Table 1). In prior studies, germinated conidida had no effect, or no significant effect, on the MICs of itraconazole, amphotericin B (for 3 to 10 A. fumigatus and A. flavus strains) (16, 18), voriconazole, and posaconazole (for A. fumigatus) (18). Therefore, the data obtained in this study are in agreement with those in previous reports for A. fumigatus and A. flavus. This report also suggests that germinated conidia had no substantial effect on the MICs for the other four Aspergillus spp. tested or on the MICs of the other new triazole, ravuconazole (Table 1).
The MFCs of the three new triazoles, amphotericin B, and itraconazole obtained with both types of conidia are listed in Table 2. Overall, both types of inocula also yielded similar fungicidal results. A prior study found no significant difference in the killing ability (killing curve experiments) of four antifungal agents against germinated and nongerminated conidia of A. fumigatus (18). Although standard conditions are not available for determination of fungicidal activities against fungi, the fungicidal activities of voriconazole (3, 15, 23, 24), posaconazole (9, 20), and ravuconazole (10) against Aspergillus spp. have been evaluated. Although prior data have been obtained by nonstandardized MFC measurement procedures, the amphotericin B and voriconazole MFC90s for A. terreus were higher (>8 µg/ml) than those for the other species tested (0.5 to 4 µg/ml) in this and other studies (20, 23). MFC ranges of the other agents similar to those listed in Table 2 have been published for Aspergillus spp. (3, 9, 10, 15, 20).
Reports of the testing of hyphal susceptibility to antifungal agents and unsuccessful attempts to standardize this procedure have been scanty (2, 11, 12, 14). A suitable hyphal suspension should contain pure, fully viable, and uniformly dispersed hyphae without mycelial mats (microcolonies). Otherwise, the density of the stock suspensions cannot be corrected or accurately diluted. Damage to viable hyphae also can occur during the appropriate grinding procedure (12), and 12 to 24 h of incubation is usually required. Unusually high amphotericin B MIC endpoints have been reported since the 1950s for A. fumigatus (11, 17) and later for A. nidulans (25) when hyphae were tested. Recently, MICs and MFCs for hyphae of other molds were substantially higher than those obtained with nongerminated conidia (13). However, hyphal and nongerminated conidial inoculum sizes were comparable for only 12 of the 50 inocula evaluated in that study. The prolonged incubation needed for hyphal growth probably increased the mycelial mass, thereby altering the size of the hyphal inoculum. In contrast, amphotericin B (2, 22) and itraconazole (5) MICs have been comparable when they were obtained by employing conidial and hyphal inocula of A. fumigatus and A. flavus. The lack of a standardized procedure by which to obtain suitable hyphal inoculum suspensions has precluded meaningful evaluations of in vitro results with a hyphal inoculum.
In conclusion, the data obtained in this and other studies indicate that MICs for isolates of Aspergillus spp. can be obtained by using a nongerminated conidial inoculum. Preparation of such suspensions is a faster, more convenient, and more economic procedure for use in the clinical laboratory than that for germinated conidial inocula. The MICs and MFCs obtained in this and other studies also suggest that interlaboratory evaluations are warranted to investigate the reliability and clinical usefulness of the determination of MFCs of both established and investigational agents for molds.
| |
FOOTNOTES |
|---|
* Mailing address: Division of Infectious Diseases, 1101 East Marshall St., Sanger Hall Room 7049, Richmond, VA 23298. Phone: (804) 8289711. Fax: (804) 8283097. E-mail: AVINGROFF{at}HSC.VCU.EDU.
| |
REFERENCES |
|---|
|
Top
Abstract
Text
References
|
|---|
| 1. |
Barry, A. L.,
M. A. Pfaller,
S. D. Brown,
A. Espinel-Ingroff,
M. A. Ghannoum,
C. Knapp,
R. P. Rennie,
J. H. Rex, and M. G. Rinaldi.
2000.
Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.
J. Clin. Microbiol.
38:3457-3459 |
| 2. |
Bezjak, V.
1985.
Standardization of a hyphal inoculum of aspergilli for amphotericin B susceptibility testing.
J. Clin. Microbol.
21:509-512 |
| 3. | Clancy, C. J., and M. H. Nguyen. 1998. The in vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur. J. Clin. Microbiol. Infect. Dis. 17:573-575[Medline]. |
| 4. | Denning, D. W., J. Y. Lee, J. S. Hostetler, P. Pappas, C. A. Kauffman, D. H. Dewsnup, J. N. Galgiani, J. R. Graybill, A. M. Sugar, A. Catanzaro, H. Gallis, J. R. Perfect, B. Dockery, W. E. Dismukes, and D. A. Stevens. 1994. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy of invasive aspergillosis. Am. J. Med. 97:135-144[CrossRef][Medline]. |
| 5. | Dupont, B., and E. Drouhet. 1987. Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results. Rev. Infect. Dis. 9:S71-S76. |
| 6. |
Espinel-Ingroff, A., and T. M. Kerkering.
1991.
Spectrophotometric method of inoculum preparation for the in vitro susceptibility testing of filamentous fungi.
J. Clin. Microbiol.
29:393-394 |
| 7. |
Espinel-Ingroff, A.,
K. Dawson,
M. Pfaller,
E. Anaissie,
B. Breslin,
D. Dixon,
A. Fothergill,
V. Paetznick,
J. Peter,
M. Rinaldi, and T. Walsh.
1995.
Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi.
Antimicrob. Agents Chemother.
39:314-319 |
| 8. | Espinel-Ingroff, A., M. Bartlett, R. Bowden, N. X. Chin, C. Cooper Jr, A. Fothergill, M. R. McGinnis, P. Menezes, S. A. Messer, P. W. Nelson, F. C. Odds, L. Pasarell, J. Peter, M. A. Pfaller, J. H. Rex, M. G. Rinaldi, G. S. Shankland, T. J. Walsh, and I. Weitzman. 1997. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J. Clin. Microbiol. 35:139-143[Abstract]. |
| 9. |
Espinel-Ingroff, A.
1998.
Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743, 872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.
J. Clin. Microbiol.
36:2950-2956 |
| 10. |
Fung-Tomc, J. C.,
E. Huczko,
B. Minassian, and D. P. Bonner.
1998.
In vitro activity of a new oral triazole, BMS-207147 (ER-30346).
Antimicrob. Agents Chemother.
42:313-318 |
| 11. | Gold, W., H. A. Stout, J. F. Pagano, and R. Donovick. 1955. -1956. Amphotericin A and B, antifungal antibiotics produced by a streptomycete. I. In vitro studies. Antibiotic Ann. 1955-1956:579-586. |
| 12. |
Granade, T. C., and W. M. Artis.
1980.
Antimycotic susceptibility testing of dermatoophytes in microcultures with a standardized fragmented mycelial inoculum.
Antimicrob. Agents Chemother.
17:725-729 |
| 13. | Guarro, J., C. Llop, C. Aguilar, and I. Pujol. 1997. Comparison of in vitro antifungal susceptibilities of conidia and hyphae of filamentous fungi. Antimicrob. Agents Chemother. 41:2760-2762[Abstract]. |
| 14. | Jahn, B., E. Martin, A. Stueben, and S. Bhakdi. 1995. Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide assay. J. Clin. Microbiol. 33:661-667[Abstract]. |
| 15. |
Johnson, E. M.,
A. Szekely, and D. W. Warnock.
1998.
In vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.
J. Antimicrob. Chemother.
42:741-745 |
| 16. |
Kitahara, M.,
V. K. Seth,
G. Medoff, and G. S. Kobayashi.
1976.
Antimicrobial susceptibility testing of six clinical isolates of Aspergillus.
Antimicrob. Agents Chemother.
9:908-914 |
| 17. | Koenig, H., and M. Kremer. 1979. A propos des discordances observees dans les resultats des les resultats des CMI faites sur spores ou filaments d'Aspergillus. Bull. Soc. Fr. Mycol. Med. 8:237-242. |
| 18. |
Manavathu, E. K.,
J. Cutright, and P. H. Chandrasekar.
1999.
Comparative study of susceptibilities of germinated and ungerminated conidia of Aspergillus fumigatus to various antifungal agents.
J. Clin. Microbiol.
37:858-861 |
| 19. | National Committee for Clinical Laboratory Standards. 1998. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Proposed standard M38-P. National Committee for Clinical Laboratory Standards, Villanova, Pa. |
| 20. | Oakley, K., C. B. Moore, and D. W. Denning. 1997. In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob. Agents Chemother. 41:1124-1126[Abstract]. |
| 21. |
Odds, F. C.,
F. V. Gerven,
A. Espinel-Ingroff,
M. S. Bartlett,
M. A. Ghannoum,
M. V. Lancaster,
M. A. Pfaller,
J. H. Rex,
M. G. Rinaldi, and T. J. Walsh.
1998.
Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models.
Antimicrob. Agents Chemother.
42:282-288 |
| 22. | Regli, P., H. Ferrari, and M. Goudard. 1980. Incidence de l'ensemencement sur les resultats de l'antibiogramme antifongique des champiognons filamenteux du genre Aspergillus. Bull. Soc. Fr. Mycol. Med. 9:269-273. |
| 23. |
Sutton, D. A.,
S. E. Sanche,
S. G. Revankar,
A. W. Fothergill, and M. G. Rinaldi.
1999.
In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.
J. Clin. Microbiol.
37:2343-2345 |
| 24. |
Verweij, P. E.,
M. F. Q. van den Bergh,
P. M. Rath,
B. E. de Pauw,
A. Voss, and J. F. G. M. Meis.
1999.
Invasive aspergillosis caused by Aspergillus ustus: case report and review.
J. Clin. Microbiol.
37:1606-1609 |
| 25. |
Warr, J. R., and J. A. Roper.
1965.
Resistance to various inhibitors in Aspergillus nidulans.
J. Gen. Microbiol.
40:273-281 |
Antimicrobial Agents and Chemotherapy, February 2001, p. 605-607, Vol. 45, No. 2
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.2.605-607.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Meletiadis, J., Antachopoulos, C., Stergiopoulou, T., Pournaras, S., Roilides, E., Walsh, T. J.
(2007). Differential Fungicidal Activities of Amphotericin B and Voriconazole against Aspergillus Species Determined by Microbroth Methodology. Antimicrob. Agents Chemother.
51: 3329-3337
[Abstract] [Full Text] -
Krishnan, S., Manavathu, E. K., Chandrasekar, P. H.
(2005). A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus. J Antimicrob Chemother
55: 914-920
[Abstract] [Full Text] -
Gomez-Lopez, A., Aberkane, A., Petrikkou, E., Mellado, E., Rodriguez-Tudela, J. L., Cuenca-Estrella, M.
(2005). Analysis of the Influence of Tween Concentration, Inoculum Size, Assay Medium, and Reading Time on Susceptibility Testing of Aspergillus spp.. J. Clin. Microbiol.
43: 1251-1255
[Abstract] [Full Text] -
Graybill, J. R., Hernandez, S., Bocanegra, R., Najvar, L. K.
(2004). Antifungal Therapy of Murine Aspergillus terreus Infection. Antimicrob. Agents Chemother.
48: 3715-3719
[Abstract] [Full Text] -
Araujo, R., Rodrigues, A. G., Pina-Vaz, C.
(2004). A fast, practical and reproducible procedure for the standardization of the cell density of an Aspergillus suspension. J Med Microbiol
53: 783-786
[Abstract] [Full Text] -
Rodriguez-Tudela, J. L., Chryssanthou, E., Petrikkou, E., Mosquera, J., Denning, D. W., Cuenca-Estrella, M.
(2003). Interlaboratory Evaluation of Hematocytometer Method of Inoculum Preparation for Testing Antifungal Susceptibilities of Filamentous Fungi. J. Clin. Microbiol.
41: 5236-5237
[Abstract] [Full Text] -
Fernandez-Torres, B., Inza, I., Guarro, J.
(2003). Comparison of In Vitro Antifungal Susceptibilities of Conidia and Hyphae of Dermatophytes with Thick-Wall Macroconidia. Antimicrob. Agents Chemother.
47: 3371-3372
[Full Text] -
Aberkane, A., Cuenca-Estrella, M., Gomez-Lopez, A., Petrikkou, E., Mellado, E., Monzon, A., Rodriguez-Tudela, J. L., the Eurofung Network,
(2002). Comparative evaluation of two different methods of inoculum preparation for antifungal susceptibility testing of filamentous fungi. J Antimicrob Chemother
50: 719-722
[Abstract] [Full Text] -
Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., Warnock, D. W.
(2001). Antifungal Susceptibility Testing: Practical Aspects and Current Challenges. Clin. Microbiol. Rev.
14: 643-658
[Abstract] [Full Text]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»